• DeutschDeutsch
  • EnglishEnglish
    • ABOUT
    • ONCOLOGY
    • PRODUCT
    • NEWS
    • INQUIRIES
    • VISIT US
ONCOSCIENCE > NEWS

ARCHIVES

  • June 2022
  • May 2022
  • November 2020
  • March 2019
  • October 2018
  • November 2017
  • August 2017
  • April 2016
  • July 2015
  • July 2010
  • October 2009
  • October 2008
  • April 2008
  • October 2007
  • September 2007
  • June 2007
  • September 2005
  • March 2005
  • January 2005
  • October 2004
  • August 2004
  • June 2004
  • March 2004
  • November 2003

SEARCH

  • Nimotuzumab on ASCO 2022

    Oncoscience | June 7th, 2022

      Once again, Nimotuzumab’s efficacy and safety in several cancer types were discussed and analyzed thorou...

  • Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer

    Oncoscience | May 28th, 2022

      This webinar was conducted on May 28th, 2022 discussing the role of Nimotuzumab in the treatment of locall...

  • Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab.

    Oncoscience | November 6th, 2020

    Specific Pharma announced today that it has entered into a supply and distribution collaboration with German based Onc...

  • Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumab

    Oncoscience | March 25th, 2019

    The results of an international clinical trial were published in March 2019. Forty-two children aged 3 to 20 years suffe...

  • Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland

    Oncoscience | October 3rd, 2018

    Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingd...

Posts navigation

1 2 3 Next
    • LEGAL NOTICE

©Copyright of Oncoscience GmbH 2023

Diese Website benutzt Cookies. Wenn du die Website weiter nutzt, gehen wir von deinem Einverständnis aus.OKDatenschutzerklärung